You are here

teclistamab

J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering

Fierce Pharma

Thu, 08/25/22 - 07:43 pm

bispecific antibodies

Multiple Myeloma

J&J goes after another FDA approval for a cancer bispecific

Pharmaforum

Thu, 12/30/21 - 10:53 am

bispecific antibodies

Multiple Myeloma

Straight after its first cancer bispecific OK, J&J highlights two more at ASCO

Pharmaforum

Tue, 05/25/21 - 10:59 am

Multiple Myeloma

ASH: J&J links subcut BCMA bispecific to 73% response rate, plots aggressive investment

Fierce Biotech

Sun, 12/6/20 - 07:10 pm

Multiple Myeloma

Johnson & Johnson's Oncology Team Posts Promising Cancer Trial Results

Motley Fool

Tue, 05/19/20 - 11:30 pm

Multiple Myeloma

bispecific antibodies

clinical trials

Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

BioSpace

Mon, 05/18/20 - 10:37 am

clinical trials

Multiple Myeloma